Edition:
United Kingdom

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.40USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$4.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
286,677
52-wk High
$9.85
52-wk Low
$4.20

Select another date:

Mon, Nov 27 2017

BRIEF-‍Inovio Pharma Cancer Vaccine Shows Promise In Preclinical Trial

* ‍INOVIO PHARMACEUTICALS SYNCON TERT CANCER IMMUNOTHERAPY COMBINED WITH CHECKPOINT INHIBITOR SYNERGISTICALLY SHRINKS TUMOR,IMPROVES SURVIVAL IN PRECLINICAL TUMOR MODEL​ Source text for Eikon: Further company coverage:

BRIEF-Inovio pharmaceuticals reports 2017 third quarter financial results

* Inovio Pharmaceuticals reports 2017 third quarter financial results

BRIEF-Inovio Pharma says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

* Inovio Pharmaceuticals says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

BRIEF-Inovio Pharma initiates immuno-oncology clinical study for glioblastoma

* Inovio Pharmaceuticals initiates immuno-oncology clinical study for glioblastoma in combination with Regeneron’S PD-1 inhibitor Source text for Eikon: Further company coverage:

BRIEF-Inovio Pharmaceuticals reports positive results from phase 1 trial of zika virus vaccine

* Inovio Pharmaceuticals Inc ‍reported on positive safety and immune response results from phase 1 trial of a vaccine against zika virus​

BRIEF-Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

* Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

BRIEF-Inovio’s cancer immunotherapy slowed PSA rise and increased PSA doubling times in patients with recurrent prostate cancer

* Inovio’s cancer immunotherapy (ino-5150) slowed PSA rise and significantly increased psa doubling times in patients with recurrent prostate cancer

BRIEF-Inovio Pharmaceuticals reports Q2 loss per share $0.13

* Inovio Pharmaceuticals reports 2017 second quarter financial results

BRIEF-Inovio Pharmaceuticals prices 12.5 mln share offering at $6 per share

* Inovio announces pricing of public offering of common stock

BRIEF-Inovio Pharmaceuticals says co has about $92 mln of cash and cash equivalents and short-term investments - SEC Filing

* Inovio Pharmaceuticals Inc - As Of June 30, co has about $92.0 million of cash and cash equivalents and short-term investments - SEC Filing Source text: [http://bit.ly/2vzazOH] Further company coverage:

Select another date: